GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

Accepting the bioequivalence (BE) study report, the Subject Expert Committee (SEC) functional under the Central Drugs ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...

Oral semaglutide, known as the oral version of Ozempic, is revolutionising chronic disease management beyond just blood sugar ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...